$TGTX News
Last published 2d ago
- 2d agoTGTXTG Therapeutics Third Quarter Conference Call - TG THERAPEUTICS INCEarnings Call TranscriptsGreetings, and welcome to the TG Therapeutics third quarter 2026 conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone sho
- 2d agoTGTXTG Therapeutics Third Quarter Conference Call - TG THERAPEUTICS INCEarnings Call TranscriptsGreetings, and welcome to the TG Therapeutics third quarter 2026 conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone sho
- 2d agoTGTXTG THERAPEUTICS, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoTGTXTG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue GuidanceBusiness WireNEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2026, along with recent company developments and provided an update on 2026 financial guidance. Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “With solid third-quarter performance and a strong ...
- 2w agoTGTXTG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026Business WireFirst reported clinical evaluation of an allogeneic CD19-directed CAR T-cell therapy in progressive MS demonstrated an encouraging preliminary safety profile with no high-grade CAR-T associated toxicities
- 3w agoTGTXTG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026Business WireSeven-year BRIUMVI data demonstrate sustained disease control, with approximately 88% of participants remaining free from confirmed disability progression after 7 years of continuous treatment Phase 1 subcutaneous
- 1mo agoTGTXTG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple SclerosisBusiness WireBRIUMVI was associated with a lower risk of 24-week confirmed disability progression and lower annualized relapse rates (ARRs) over five years compared with ocrelizumab and ofatumumab TG Therapeutics, Inc.
- 1mo agoTGTXTG Therapeutics Announces Schedule of Data Presentations at MSToronto2026Business WireLate-breaking oral presentation will highlight initial clinical results evaluating azer-cel, an allogeneic "off-the-shelf" CD19-directed CAR T-cell therapy, in patients with progressive multiple
- 1mo agoTGTXKuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TG Therapeutics, Inc. (NASDAQ: TGTX)...
- 2mo agoQNTMNVSMRKTGTX+1Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics MarketGlobeNewswireAUSTIN, Texas, Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Today's multiple sclerosis treatments can slow down disease progression, but none of them halt it outright, and none give back the
- 2mo agoTGTXTG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireNEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 28th
- 2mo agoTGTXTG Therapeutics to Participate in the Cantor Global Healthcare ConferenceGlobeNewswireNEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Cantor Global
- 3mo agoDTILTGTXPrecision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business UpdateBusiness Wire- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining - - In late-breaking data at EASL,
- 3mo agoTGTXTG Therapeutics Second Quarter Conference Call - TG THERAPEUTICS INCEarnings Call TranscriptsGreetings. Welcome to TG Therapeutics' second quarter conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require
- 3mo agoTGTXTG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue GuidanceGlobeNewswireSecond quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million Raises full year 2026 total global revenue target to approximately $950
- 3mo agoTGTXTG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business UpdateGlobeNewswireNEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, August 3, 2026, at 8:30 AM ET to discuss results for the second quarter
- 3mo agoTGTXKuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TG Therapeutics, Inc. (NASDAQ: TGTX)...
- 3mo agoTGTXKuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law FirmGlobeNewswireNEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TG Therapeutics, Inc. (NASDAQ:TGTX) breached their fiduciary
- 4mo agoTGTXTG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant SchizophreniaGlobeNewswireNEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant
- 4mo agoQNTMNVSMRKTGTX+1The Quest to Repair What Multiple Sclerosis Takes AwayGlobeNewswireAUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis ("MS") gradually strips people of command over their own bodies, advancing steadily with no available cure.
- 5mo agoTGTXTG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 TrialGlobeNewswire82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11) Potential registration-directed Phase 2 trial
- 5mo agoTGTXTG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)GlobeNewswirePharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027
- 5mo agoTGTXTG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare ConferenceGlobeNewswireNEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Goldman Sachs 47th
- 5mo agoTGTXTG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in ImmunologyGlobeNewswireTreatment with BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients BRIUMVI demonstrated significant improvements across disability, MRI outcomes, and no evidence of disease
- 5mo agoTGTXTG Therapeutics to Participate in the Jefferies Global Healthcare ConferenceGlobeNewswireNEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Jefferies Global
- 5mo agoTGTXTG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE TrialGlobeNewswirePhase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infusion on Day 1 only Safety and tolerability
- 5mo agoTGTXTG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual MeetingGlobeNewswireNEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in adults with relapsing forms
- 6mo agoTGTXTG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue GuidanceGlobeNewswireFirst quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 million Raises full year 2026 total global revenue target to approximately $925 million and
- 6mo agoDTILTGTXPrecision BioSciences Reports First Quarter 2026 Financial Results and Provides Business UpdateBusiness Wire- Continued advancement of the Phase 1/2a ELIMINATE-B trial of PBGENE-HBV across multiple dosing cohorts; Late-Breaking poster presentation for PBGENE-HBV accepted at European Association for the Study of the Liver
- 6mo agoTGTXTG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business UpdateGlobeNewswireNEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Wednesday, May 6, 2026, at 8:30 AM ET to discuss results for the first quarter 2026
- 6mo agoTGTXTG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual MeetingGlobeNewswireNEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple
- 7mo agoTGTXTG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVIGlobeNewswirePhase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 months Top-line data expected year-end 2026/ first quarter 2027 NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) --
- 8mo agoDTILTGTXPrecision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business UpdateBusiness Wire- PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity - - Strong Phase 1 ELIMINATE-B trial execution
- 8mo agoTGTXData Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple SclerosisGlobeNewswireNEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the publication of data from a post hoc pooled analysis of the Phase 3 ULTIMATE I and II studies evaluating
- 8mo agoTGTXTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual MeetingGlobeNewswireNEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing
- 8mo agoDTILTGTXPrecision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple SclerosisBusiness Wire– Milestone payments include $5.25 million cash and $2.25 million purchase of Precision stock– – Cash received supports Precision's expected cash runway through 2028 and strategic focus on in vivo gene editing
- 8mo agoTGTXTG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue GuidanceGlobeNewswireFourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively Target guidance of approximately $875-900
- 8mo agoTGTXTG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business UpdateGlobeNewswireNEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Thursday, February 26, 2026, at 8:30 AM ET to discuss results for the fourth quarter
- 8mo agoTGTXLong Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple SclerosisGlobeNewswireDuring year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained consistent over 5 years
- 9mo agoTGTXTG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple SclerosisGlobeNewswireA Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, Feb. 08, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced a collaboration with actress
- 9mo agoTGTXTG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual ForumGlobeNewswireNEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for
- 9mo agoTGTXTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual ForumGlobeNewswireNEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas
- 10mo agoTGTXApproval of Briumvi, Bla #761238FDA Approved DrugsApproval Date: 01/16/2026; Drug Name: Briumvi, Bla #761238; Active Ingredients: UBLITUXIMAB-XIIY; Company: Tg Therapeutics, Inc; Submission Status: Approval; Application Number: 761238
- 10mo agoTGTXTG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development MilestonesGlobeNewswirePreliminary total global full year 2025 revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year 2025 net product revenue of approximately $182 million and $594 million,
- 11mo agoTGTXTG Therapeutics to Participate in the 8th Annual Evercore Healthcare ConferenceGlobeNewswireNEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the 8th Annual Evercore
- 11mo agoTGTXTG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America's Fastest-Growing CompaniesGlobeNewswireNEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced it ranked number 27 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media,
- 1y agoTGTXTG Therapeutics to Participate in the TD Cowen Immunology & Inflammation SummitGlobeNewswireNEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the TD Cowen Immunology
- 1y agoTGTXTG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue GuidanceGlobeNewswireThird quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million Raises full year 2025 global revenue target to $600 million, and raises full year BRIUMVI U.S. net revenue target
- 1y agoTGTXTG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business UpdateGlobeNewswireNEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, November 3, 2025, at 8:30 AM ET to discuss results for the third quarter of
- 1y agoTGTXTG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVIGlobeNewswireNEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated Day 1 and